Menu Search
Equities

Aptose Biosciences Inc

  • Add to watchlist
  • Add to portfolio
  • Add an alert
0UI8:LSE

Aptose Biosciences Inc

Actions
  • Price (CAD)--
  • Today's Change--
  • Shares traded--
  • 1 Year change--
  • Beta0.4365
Data delayed at least 20 minutes, as of Mar 24 2025.
More ▼
Notice
Important Notice
Please note that effective 5th February, 2026 the Financial Times will no longer publish or present securities from the Nairobi Stock Exchange.

Profile data is unavailable for this security.

About the company

Aptose Biosciences Inc. is a clinical-stage biotechnology company focused on developing precision medicines addressing unmet medical needs in oncology, with an initial focus on hematology. The Company’s lead clinical-stage, oral kinase inhibitor tuspetinib (TUS) has demonstrated activity as a monotherapy and in combination therapy in patients with relapsed or refractory acute myeloid leukemia (AML) and is being developed as a frontline triplet therapy in newly diagnosed AML. The Company's small molecule cancer therapeutics pipeline includes products designed to provide single agent efficacy and to enhance the efficacy of anti-cancer therapies and regimens without overlapping toxicities. Its Luxeptinib (LUX) is being developed for the treatment of patients with certain B-cell malignancies, including chronic lymphocytic leukemia (CLL), small lymphocytic lymphoma (SLL), and certain non-Hodgkin’s lymphomas (NHL) who are resistant or intolerant to conventional treatments.

  • Revenue in USD (TTM)0.00
  • Net income in USD-19.29m
  • Incorporated2006
  • Employees13.00
  • Location
    Aptose Biosciences Inc66 Wellington Street WestSuite 5300,, TD Bank Tower Box 48TORONTO MK5 1E6CanadaCAN
  • Phone+1 (647) 479-9828
  • Fax+1 (416) 798-2200
  • Websitehttps://aptose.com/
More ▼
Data Provided by LSEG
All markets data located on FT.com is subject to the FT Terms & Conditions
All content on FT.com is for your general information and use only and is not intended to address your particular requirements. In particular, the content does not constitute any form of advice, recommendation, representation, endorsement or arrangement by FT and is not intended to be relied upon by users in making (or refraining from making) any specific investment or other decisions.
Any information that you receive via FT.com is at best delayed intraday data and not "real time". Share price information may be rounded up/down and therefore not entirely accurate. FT is not responsible for any use of content by you outside its scope as stated in the FT Terms & Conditions.